The healthcare CMO market offers contract manufacturing services to pharmaceutical, biotechnology companies and medical device companies. Healthcare CMOs provide drug development and manufacturing services including clinical trials manufacturing, commercial manufacturing, packaging and labeling among others. There is growing demand for generic drugs and biosimilars globally owing to patent expiries of blockbuster drugs and rising healthcare costs which is fueling growth of healthcare CMO market. The market players are also focusing on developing large-scale manufacturing facilities and expanding their capability to produce complex molecules.
The Global healthcare CMO Market is estimated to be valued at US$ 507.46 Mn in 2024 and is expected to exhibit a CAGR of 5.4% over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the Healthcare CMO Market Demand are FMC Corporation, BASF SE, Bayer AG, Sumitomo Chemical Co., Ltd., Syngenta AG, Adama Agricultural Solutions Ltd., UPL Limited (previously United Phosphorus Limited), Nufarm Limited, Tagros Chemicals India Ltd., Heranba Industries Limited. FMC Corporation is one of the leading players and offers integrated solutions for drug development and commercial manufacturing.
The key opportunities in the market include growing outsourcing of clinical trial supplies and commercial production by pharmaceutical companies. There is also growing demand for vaccine manufacturing which is driving more pharmaceutical companies to rely on CMOs for production.
The healthcare CMOs are expanding their presence globally especially in emerging markets of Asia Pacific and Latin America to tap the growth opportunities. Many players are also focusing on acquisitions to enhance their manufacturing capabilities and expand service offerings.
Market drivers
The growing generic drug market is a major driver for healthcare CMO market. The patent cliff of many blockbuster drugs and rising healthcare costs has increased the demand for low cost generic drugs globally. This is driving more work outsourcing to CMOs by pharmaceutical companies.
Market restraints
Regulatory compliance and quality control are major challenges for healthcare CMOs. Any deviation can impact overall operations and profitability of pharmaceutical clients. This makes them dependent on CMOs capabilities and risk averse to outsource critical manufacturing activities. Stringent regulations also increase operating costs of CMOs.
Segment Analysis
The Healthcare CMO market comprises pharmaceutical CMO, medical device CMO, and dental CMO. Among these, the pharmaceutical CMO segment currently dominates the global market with over 40% market share, owing to large outsourcing volumes from pharmaceutical companies for manufacturing of drug substances, formulations, and biologics. Contract manufacturing helps pharmaceutical companies reduce costs as well as focus on drug development and marketing activities. The biologics segment will witness high growth in coming years due to patent expiries of large drugs and increasing demand for biosimilars.
Global Analysis
North America leads the global Healthcare CMO market with over 35% share, supported by presence of major pharma players in the region that outsource significant manufacturing volumes. However, Asia Pacific will emerge as the fastest growing regional market during the forecast period due to increasing outsourcing from multinational companies to capitalize on low-cost skilled labor. Countries like India and China have emerged as major contract manufacturing hubs and are attracting high foreign investments for establishing manufacturing facilities. Moreover, expanding healthcare infrastructure and rising medical tourism in Asia Pacific economies are catalysing the regional market growth.
Get more insights on Healthcare CMO Market
Also read related article on Global Quick E-Commerce (Quick Commerce) Market
Comments
0 comment